Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter of 2008
Date:8/7/2008

- Isis ends the second quarter with more than $535 million in cash

- Conference Call Webcast Thursday, August 7, 8:30 a.m. EDT at

http://www.isispharm.com

CARLSBAD, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the second quarter ended June 30, 2008. The Company ended the quarter in the strongest financial position in its history with more than $535 million of cash and $873,000 of pro forma operating income in the second quarter.

"Over the last year we have added significant cash through our recent collaborations. More importantly, as our corporate alliances continue to be successful, we will continue to add cash to our balance sheet and revenue to our P&L. We remain on track to end 2008 with more than $450 million in cash and to meet our pro forma net operating loss guidance of less than $15 million for the year," commented B. Lynne Parshall, COO and CFO of Isis.

"Our strong financial position is a result of the successful execution of our business strategy, enabled by the efficiency of our antisense technology. The transactions we have completed balance both our short-term and long-term objectives. In addition, the maturation of our satellite companies is providing exactly the types of financial benefits for which they were created," continued Ms. Parshall. "Because of our partnering successes, we have reported our second profitable quarter in the past year. While we are not yet at the point of sustainable profitability and our quarter-to-quarter performance will continue to fluctuate based on one-time events such as the Teva-ATL license fee, our si
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
2. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Caliper Life Sciences Reports Second Quarter 2008 Results
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. EntreMed Reports Second Quarter 2008 Financial Results
6. Transgenomic Reports Second Quarter 2008 Results
7. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
8. Bionovo Reports Second Quarter 2008 Financial Results
9. AtriCure Reports Record Second Quarter 2008 Financial Results
10. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
11. eResearchTechnology Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22 de enero de 2015  El Dr. Paul ... llamada a nominaciones para 2015. Este prestigioso premio reconoce ... tiene el potencial para hacer, contribuciones destacadas para la ... hasta el 15 de marzo de 2015 a través ...
(Date:1/22/2015)... 22, 2015   GenoSpace , a precision medicine software company ... the broad use of genomic, imaging and other biomedical data ... Michelle Munson , CEO of Aspera, an IBM Company, ... - http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... BOTHELL, Wash. , Dec. 24, 2014   BioLife Solutions ... manufacturer and marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" or ... Annual Meeting of Stockholders on May 4, 2015 (the "Annual ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... will be one of the presenters at Digestive Disease ... in interventional gastroenterologyORANGEBURG, S.C., May 29 Zeus, Inc., ... it has been invited to present at Digestive Disease ... Dr. Bruce Anneaux, Ph.D. and GI Endoscopy Specialist Aubrey ...
... May 29 Dey L.P., a subsidiary of Mylan ... it has begun to market and distribute EMSAM(R) in ... monoamine oxidase inhibitor (MAOI), which was approved by the ... the treatment of major depressive disorder. EMSAM previously was ...
... have designed cells that can count and "remember" cellular events, ... activated in a specific order. , Such circuits, which mimic ... the number of times a cell divides, or to study ... biosensors that count exposures to different toxins. , The team ...
Cached Biology Technology:Zeus to Present at Digestive Disease Week in Chicago 2Dey L.P. to Market EMSAM(R) Skin Patch for Treatment of Major Depressive Disorder 2MIT, BU engineer cellular circuits that count events 2MIT, BU engineer cellular circuits that count events 3
(Date:1/22/2015)... , Jan. 22, 2015 Infinisource has launched its new ... G2 model. The G2 sets a higher standard for collecting ... capital management solution. With plug-and-play installation, touch screen interface and ... provides a robust time collection solution for the small to ...
(Date:12/22/2014)... 22, 2014  The 2014 Holiday Season may be the ... Intelligence reports that the long anticipated floodgates for consumer ... demand for smart phones, tablets, and wearable mobile devices ... 2.5 billion users with nearly 4.8 billion biometric devices ...
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ...
Breaking Biology News(10 mins):Infinisource's NXG series sets new time clock standard 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... University School of Medicine studies of Hispanic farmworkers in North ... had skin disease and that workers need more information about ... deadly diseases such as skin cancer. , Few studies have ... Wake Forest studies, 59 farmworkers from Nash and Johnston Counties ...
... most effective chemotherapy drugs against cancer is cisplatin because ... it also kills healthy tissue. Many scientists are creating ... treatments without side effects. One approach to analog development ... a Virginia Tech chemistry-biology research team that has been ...
... ensure complete tumor removal at breast cancer excision is ... used light waves in a newly explored region of ... and determine if the removed tissue margins were clear ... potential to eliminate the need for multiple surgeries and ...
Cached Biology News:Skin disease common among Hispanic farmworkers in North Carolina, research shows 2Light activated anticancer drug targeted to DNA using cisplatin like sub-units 2Terahertz imaging may reduce breast cancer surgeries 2
Human RXR beta/NR2B2 MAb (Clone H7341) Keywords: RXRbeta, RXRbeta, Retinoid X Receptor beta...
Human SOST Affinity Purified Polyclonal Ab...
BOND ELUT MATRIX-C18, 25 mg ...
Prepared from plasminogen by activation with immobilized human uPA...
Biology Products: